Amgen reported strong quarterly growth and raised its full-year guidance, reflecting robust sales across key products and a positive outlook on its pipeline. Managementâ€™s confident tone and strategic initiatives to counter biosimilar threats further support investor optimism. These factors are likely to positively influence the stock in the short term.

[1]